Targeted treatment for chronic lymphocytic leukemia

被引：5

作者：

Masood, Aisha ^{[2
]}

Sher, Taimur ^{[3
]}

Paulus, Aneel ^{[3
]}

Miller, Kena C. ^{[3
]}

Chitta, Kasyapa S. ^{[4
]}

Chanan-Khan, Asher ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA

[2] Mt Sinai Sch Med, Tisch Canc Inst, Bone Marrow Transplant Unit, New York, NY USA

[3] Roswell Pk Canc Inst, Dept Med, New York, NY USA

[4] Roswell Pk Canc Inst, Dept Mol Targets & Expt Therapeut, New York, NY USA

来源：

ONCOTARGETS AND THERAPY | 2011年 / 4卷

关键词：

CLL; Akt inhibitors; Bcl-2; inhibitors; cyclin d kinase inhibitors; heat shock protein inhibitors; immunomodulatory drugs; monoclonal antibodies; NON-HODGKINS-LYMPHOMA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PHASE-I; INITIAL THERAPY; MONOCLONAL-ANTIBODY; UNTREATED PATIENTS; CLINICAL-EFFICACY; 1ST-LINE THERAPY; ANTI-CD20; MAB; CELL LYMPHOMA;

D O I：

10.2147/OTT.S7173

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.

引用

页码：169 / 183

页数：15

共 50 条

[21] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia [J].

Hill, Brian T. ;

Kalaycio, Matt .

ONCOTARGETS AND THERAPY, 2015, 8 :2391-2397

[22] Potential of BCL2 as a target for chronic lymphocytic leukemia treatment [J].

Moia, Riccardo ;

Diop, Fary ;

Favini, Chiara ;

Kodipad, Ahad Ahmed ;

Gaidano, Gianluca .

EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) :391-402

[23] Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia [J].

Lipsky, Andrew H. ;

Lamanna, Nicole .

CANCER, 2023, 129 (01) :18-31

[24] Targeted therapy for chronic lymphocytic leukemia [J].

Alfonso Quintás-Cardama ;

Susan O’Brien .

Targeted Oncology, 2009, 4 :11-21

[25] Targeted Therapy for Chronic Lymphocytic Leukemia: A Glimpse Into the Future [J].

Hillmen, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :469-470

[26] How to improve the treatment outcome in chronic lymphocytic leukemia? [J].

Robak, Tadeusz .

LEUKEMIA RESEARCH, 2010, 34 (03) :272-275

[27] Therapeutic advancement of chronic lymphocytic leukemia [J].

Lu, Kang ;

Wang, Xin .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5

[28] New Agents in Chronic Lymphocytic Leukemia [J].

Lin, Thomas S. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2010, 5 (01) :29-34

[29] Importance of genetics in chronic lymphocytic leukemia [J].

Zenz, Thorsten ;

Mertens, Daniel ;

Doehner, Hartmut ;

Stilgenbauer, Stephan .

BLOOD REVIEWS, 2011, 25 (03) :131-137

[30] Ofatumumab for the treatment of chronic lymphocytic leukemia [J].

Grosicki, Sebastian .

EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (03) :265-272

← 1 2 3 4 5 →